Cowen analyst Steve Scala reiterated an Outperform rating and $66.00 price target on AstraZeneca (NASDAQ: AZN) ahead of a year ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE